286 related articles for article (PubMed ID: 16308974)
1. [Prognostic and predictive factors in breast cancer].
Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE
Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
3. [Biological features of breast cancer in patients under 35].
Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
[TBL] [Abstract][Full Text] [Related]
4. Molecular prognostic factors for breast cancer metastasis and survival.
Esteva FJ; Sahin AA; Cristofanilli M; Arun B; Hortobagyi GN
Semin Radiat Oncol; 2002 Oct; 12(4):319-28. PubMed ID: 12382190
[TBL] [Abstract][Full Text] [Related]
5. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
6. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
7. [Expression of estrogen and progesterone receptors and oncoprotein HER-2 as a marker for clinical course and outcome in endometrioid adenocarcinoma of the uterine body (immunohistologic study)].
Samsonova EA; Maksimova NA; Urmancheeva AF; Pozharisskiĭ KM
Vopr Onkol; 2004; 50(2):196-201. PubMed ID: 15176223
[TBL] [Abstract][Full Text] [Related]
8. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
Dowsett M; Dunbier AK
Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018
[TBL] [Abstract][Full Text] [Related]
9. [Pathologic diagnosis and histopathology record of breast cancer].
Cserni G; Francz M; Járay B; Kálmán E; Kovács I; Kulka J; Orosz Z; Udvarhelyi N; Vass L
Magy Onkol; 2010 Sep; 54(3):217-26. PubMed ID: 20870599
[No Abstract] [Full Text] [Related]
10. Biological markers in breast cancer prognosis and treatment.
Kesisis G; Kontovinis LF; Gennatas K; Kortsaris AH
J BUON; 2010; 15(3):447-54. PubMed ID: 20941809
[TBL] [Abstract][Full Text] [Related]
11. Tumour-related factors and prognosis in breast cancer detected by screening.
Olsson A; Borgquist S; Butt S; Zackrisson S; Landberg G; Manjer J
Br J Surg; 2012 Jan; 99(1):78-87. PubMed ID: 22068957
[TBL] [Abstract][Full Text] [Related]
12. Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board.
Ellis MJ
J Natl Cancer Inst; 2008 Feb; 100(3):159-61. PubMed ID: 18230793
[No Abstract] [Full Text] [Related]
13. [Steroid hormone receptor status and other immunohistochemical prognostic markers in benign and malignant diseases of the breast].
Nizze H; al-Thobhani AK; Terpe H
Zentralbl Chir; 1998; 123 Suppl 5():14-8. PubMed ID: 10063564
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for breast cancer and their use in the clinical setting.
Kapoor A; Vogel VG
Expert Rev Anticancer Ther; 2005 Apr; 5(2):269-81. PubMed ID: 15877524
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors in breast cancer patients].
Roisman I; Peretz T; Reznick AZ; Lifshitz I; Bitterman A; Fares F; Toledano H; Barzilay A; Durst AL
Harefuah; 1996 May; 130(10):693-9. PubMed ID: 8794662
[No Abstract] [Full Text] [Related]
16. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
17. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
18. The importance of prognostic factors in premenopausal women with breast cancer.
Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
[TBL] [Abstract][Full Text] [Related]
19. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
20. Molecular and genetic markers in the local-regional management of breast cancer.
Haffty BG
Semin Radiat Oncol; 2002 Oct; 12(4):329-40. PubMed ID: 12382191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
